Clinical trials: First Pregnancy
Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma
[177Lu]Lu-AKIR001 First-in-human Study
The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in…
- Conditions
- Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, Cancer Head and Neck, Cervix Carcinoma
- Trial name
- AKIR001 (NCT06639191)
- Testing
- [177Lu]Lu-AKIR001
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Karolinska University Hospital
HIV, Infant Exposure to Efavirenz
Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART
To characterize safety, durability, antiretroviral treatment (ART) resistance, and clinical outcomes for mothers and infants exposed to the efavirenz-based Option B+ regimen for Prevention of Mother to Child Transmission (PMTCT)…
- Trial name
- S4 (NCT02249962)
- Where
- Malawi
- Volunteers
- 12,011 people
- Sponsor
- University of North Carolina, Chapel Hill
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004082
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Fetus Disorder
AutoFUSE or First-Trimester Ultrasound Scan
The goal of this clinical trial is to validate the clinical application capabilities of AutoFUSE. The main questions it aims to answer are: Does AutoFUSE reduce the time required to obtain standard planes in first-trimester…
- Trial name
- NCT07601191
- Testing
- AutoFUSE system, Traditional ultrasound scan
- Where
- 3 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Calculous Anuria, Upper Ureteral Stone
Initial Drainage Method and Flexible Ureteroscopy Outcomes in Calculous Anuria
Calculous anuria caused by obstructing upper ureteral stones in a solitary functioning kidney is a urological emergency requiring urgent decompression.
- Conditions
- Calculous Anuria, Upper Ureteral Stone, Obstructive Uropathy, Acute Kidney Injury
- Trial name
- NCT07627880
- Testing
- Initial JJ Ureteral Stent Drainage, Initial Percutaneous Nephrostomy Drainage
- Where
- 3 sites in Egypt
- Volunteers
- 90 people
- Sponsor
- Beni-Suef University
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie
Neoplasm, Gynecologic
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
First in Human study, assessing the safety profile, the pharmacokinetics and preliminary antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with previously treated gynecological cancers bearing the…
- Trial name
- NCT02978755
- Testing
- GM102, GM102 escalating doses
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 78 people
- Sponsor
- GamaMabs Pharma
Cesarean Section Complications, Tranexamic Acid
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section
Cesarean section is the most prevalent operation among women globally, 10-15% (1, 2). Recent research has shown Egypt to be the third-largest country globally, with an estimated 52% cesarean sections (3).
- Conditions
- Cesarean Section Complications, Tranexamic Acid, Oxytocin, Post Partum Hemorrhage
- Trial name
- NCT06010368
- Testing
- Tranexamic acid injection, Oxytocin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Cairo University
Prostate Cancer, Erectile Dysfunction
Pentafecta Outcomes After Robot-assisted Laparoscopic Radical Prostatectomy
Robot-assisted laparoscopic radical prostatectomy (RALRP) is a surgical technique for the treatment of prostate cancer. The aim of this study was to report our initial experience with RALRP, by applying the concept of pentafecta.
- Conditions
- Prostate Cancer, Erectile Dysfunction, Complication of Surgical Procedure, Urinary Incontinence
- Trial name
- NCT03706508
- Testing
- Robot-assisted laparoscopic radical prostatectomy
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Fallopian Tube Cancer, Ovarian Cancer
Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- AGO-OVAR9 (NCT00052468)
- Testing
- TCG, TC
- Where
- 17 sites in Denmark, France and 2 more
- Volunteers
- 1,742 people
- Sponsor
- AGO Study Group
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00028743
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 28 sites in Canada
- Volunteers
- 819 people
- Sponsor
- NCIC Clinical Trials Group
Pregnancy Complication
Effect of Exercise on Mode of Delivery in Elderly Primigravida With Rigid Perineum
Objective of the study is to explore effect of therapeutic exercise program on mode of delivery in elderly primigravida with rigid perineum. women.
- Trial name
- NCT07771543
- Testing
- Therapeutic exercise program, control group advice
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Beni-Suef University
Idiopathic Growth Hormone Deficiency, Turner Syndrome
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
PREDICT Validation is a validation pharmacogenetic trial. The purpose of this study is to confirm that some genes can be used to predict how well a subject diagnosed with idiopathic growth hormone deficiency (IGHD) or turner…
- Trial name
- NCT01419249
- Testing
- Blood sampling
- Where
- 31 sites in Argentina, Canada and 7 more
- Volunteers
- 458 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cervical Intraepithelial Neoplasia Grade 2/3, Carcinoma Cervix
Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples
The "Extended VALHUDES" study is a Clinical Performance / Diagnostic Test Accuracy Study that aims to extend validation, achieved as part of the "Belgian VALHUDES", of HPV testing using BD Onclarity on samples collected using…
- Trial name
- Ext-VALHUDES (NCT04788849)
- Testing
- BD Onclarity™ HPV assay
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- University of Milano Bicocca
Metastatic Renal Cell Carcinoma
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
Sunitinib given at 50 mg/day on schedule 4/2 (4 weeks on treatment, 2 weeks off) is the standard care for first-line treatment of metastatic renal cell carcinoma, but the schedule was reported with a high rate of dose reduction…
- Trial name
- NCT02398552
- Testing
- Sunitinib
- Where
- 6 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Cervical Cancer
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
Chemoradiotherapy has become the standard of care for women with locally advanced cervical cancer. The available data support a 30 to 50% reduction in the risk of death from cervical cancer for women with locally advanced disease…
- Trial name
- NCT01088347
- Testing
- mapatumumab, cisplatin, radiotherapy
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- University Medical Center Groningen
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
- Trial name
- NCT01284205
- Testing
- Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
- Where
- 14 sites in United States
- Sponsor
- Bioniche Life Sciences Inc.
Miscarriage
Serum Kisspeptin: a Predictive Marker of Miscarriage or Not?
This is a prospective observational study. Eligible women undergo ART treatment in our centre will be recruited for the study and each woman will only be included in the study once. Informed written consent will be obtained.
- Trial name
- NCT03940495
- Where
- China
- Volunteers
- 182 people
- Sponsor
- ShangHai Ji Ai Genetics & IVF Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.